Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Featured trial
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer

Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.

  • 0 views
  • 15 Oct, 2021
Enfortumab Vedotin and Pembrolizumab With or Without Chemotherapy vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together alone or with platinum chemotherapy to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients …

pembrolizumab
transitional cell carcinoma
carboplatin
adjuvant
cancer
  • 0 views
  • 16 Feb, 2024
  • 26 locations
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).

renal function
pet-ct scan
pegaspargase
arrhythmia
PET-CT
  • 0 views
  • 16 Feb, 2024
  • 1 location
Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

This study is designed to observe and evaluate the safety and the efficacy of the anti-programmed-death-1 antibody (anti-PD-1) Triprilumab in combination with chemotherapy of Gemcitabine PLUS Cisplatin in patients who were advanced intrahepatic cholangiocarcinoma with no chance for primary surgery.

  • 0 views
  • 05 Aug, 2020
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer

Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.

  • 0 views
  • 15 Oct, 2021
  • 1 location
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer

Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.

  • 0 views
  • 15 Oct, 2021
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

To explore the safety and synergy of the proposed combinatorial approach, participants with locally advanced PC will receive nivolumab and ipilimumab administered in combination with gemcitabine and nab-paclitaxel followed by immune-chemoradiation.

cancer chemotherapy
teratogenicity
neutrophil count
celiac disease
pancreatic cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.

b-cell lymphoma
lenalidomide
diffuse large b-cell lymphoma
gemox
lymphoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
PAXG Out in the Country

The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.

serum total bilirubin level
paclitaxel
pdac
pancreatic ductal adenocarcinoma
neutrophil count
  • 0 views
  • 05 Aug, 2020
Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

A prospective multicentre pilot study which includes patients 70 years-old diagnosed of unresectable hilar cholangiocarcinoma (hCCA) 3cm in radial diameter, without evidence of lymph node or distant metastases. Liver transplantation preceded by neoadjuvant radio-chemotherapy will be performed in this selected group. The primary endpoint will be overall survival at 1, …

  • 0 views
  • 16 Feb, 2024
  • 1 location